Phreesia (PHR) director Jon Kessler submits initial Form 3 ownership
Phreesia, Inc. director Jon Kessler has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing identifies Kessler as a director but does not report any stock transactions or derivative positions, serving solely as a baseline disclosure of his insider status without indicating stock activity. The SEC Form 3 formally establishes his insider reporting obligations.
Raymond James cuts Phreesia stock price target on pharma ad headwinds
Raymond James has lowered its price target for Phreesia Inc. (NYSE:PHR) to $16 from $25, while maintaining an Outperform rating, due to headwinds in pharmaceutical advertising. Phreesia also reduced its fiscal 2027 revenue guidance by about 7% due to lower visibility in pharma ad spending, despite reporting better-than-expected Q4 fiscal 2026 results and maintaining its adjusted EBITDA guidance through cost controls. Other analysts like BMO Capital and DA Davidson also adjusted their price targets downwards, though KeyBanc maintained an Overweight rating.
PHR Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Phreesia Inc (PHR), concluding with a "Strong Sell" consensus based on various indicators. It details moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels for the stock. PHR is currently trading significantly below its 200-day moving average, and its RSI indicates it is in oversold territory.
Phreesia Investors Urged to Join Fraud Investigation
The Schall Law Firm has announced an investigation into potential securities law violations by Phreesia, Inc. (NYSE: PHR), a healthcare technology company. The probe is based on claims that Phreesia may have made false or misleading statements to investors, impacting its stock price. Investors are encouraged to contact the firm to learn more about participating in the investigation.
Phreesia Investors Invited to Join Fraud Investigation
The Schall Law Firm has initiated an investigation into Phreesia, Inc. (NYSE: PHR) following concerns about potential securities law violations. This inquiry stems from the company's Q4 2026 financial results and reduced revenue guidance for FY 2027, which caused a sharp drop in its stock price. Investors are encouraged to contact the law firm to discuss their rights and join the investigation into Phreesia's financial reporting and transparency.
[8-K] Phreesia, Inc. Reports Material Event
Phreesia, Inc. (PHR) reported strong Q4 fiscal 2026 results, surpassing $100 million in adjusted EBITDA and achieving positive GAAP net income for the first time. However, the company reduced its fiscal 2027 revenue outlook due to decreased visibility and commitments from certain pharmaceutical and public health clients in its network solutions business, particularly impacting the second half of the year. Despite the revenue reduction, Phreesia maintained its adjusted EBITDA guidance, citing operational leverage, cost discipline, and efficiency gains from AI.
PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Phreesia, Inc. (NYSE: PHR) on behalf of investors for potential securities law violations. This investigation follows Phreesia's Q4 2026 financial results, where the company reduced its revenue guidance for FY 2027, citing weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment, leading to a sharp decline in stock value. Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Changed?
Phreesia (PHR) cut its fiscal 2027 revenue outlook to US$510 million–US$520 million, down from a previously more bullish forecast, due to reduced visibility into pharmaceutical client spending. This guidance cut has led to a 25.5% drop in stock price and raises questions about the company's growth trajectory and the stability of its Network Solutions revenue. Investors are now re-evaluating Phreesia's investment narrative, with analysts noting a significant disparity in fair value estimates.
Pale fire capital buys Phreesia (PHR) shares worth $10.4 million
Pale Fire Capital SE and related entities have collectively purchased $10.4 million worth of Phreesia (NASDAQ:PHR) common stock between March 31 and April 2, 2026. These purchases occurred as Phreesia's shares traded near their 52-week low, despite the company reporting better-than-expected Q4 fiscal 2026 results. The stock has seen mixed reactions from analysts due to a downgraded fiscal 2027 revenue outlook, primarily attributed to reduced pharmaceutical advertising spend.
Pale fire capital buys Phreesia (PHR) shares worth $10.4 million
Pale Fire Capital SE and related entities have invested $10.4 million in Phreesia (PHR) shares through a series of purchases between March 31 and April 2, 2026. This comes as Phreesia shares trade near a 52-week low despite better-than-expected Q4 fiscal 2026 results. Analysts have mixed reactions due to a downgraded fiscal 2027 revenue outlook, leading to varied price target adjustments and stock rating changes.
Pale Fire Capital (PHR) discloses 8.9M-share, 14.7% stake in Phreesia
Pale Fire Capital, through its affiliated Czech entities and individuals, has disclosed an 8,924,329-share stake in Phreesia (PHR), representing 14.7% of the company's outstanding shares. The aggregate purchase price for this position was approximately $103.5 million, funded from working capital, potentially including margin loans. While the filing highlights a significant shareholder position, it does not outline any new strategic agenda, with Pale Fire Capital and its principals disclaiming beneficial ownership of securities not directly owned.
Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Changed?
Phreesia (PHR) recently cut its fiscal 2027 revenue outlook to US$510 million–US$520 million due to reduced visibility into pharmaceutical client spending, leading to a 25.5% stock drop. This guidance cut challenges the previous optimistic investment narrative, which relied on strong Network Solutions growth and pharma budgets. Investors are now re-evaluating the company's future prospects, especially concerning revenue per average healthcare services client (AHSC) growth.
Citizens downgrades Phreesia stock rating after Q4 results
Citizens downgraded Phreesia Inc. (NYSE:PHR) to Market Perform from Market Outperform despite better-than-expected Q4 fiscal 2026 results. The healthcare software company reported non-GAAP EPS of $0.33 and total revenue of $127.1 million, but shares fell 27% due to a slowdown in organic growth and a reduction in fiscal 2027 revenue guidance. This guidance cut is attributed to decreased advertising spend from pharmaceutical clients, leading several financial firms to revise their price targets downwards.
Phreesia (NYSE: PHR) outlines $24B opportunity and AccessOne expansion
Phreesia (NYSE: PHR) has detailed its platform growth and a $24 billion total addressable market opportunity, showcasing its diversified revenue model across subscriptions, payment solutions, and Network Solutions. The company's recent acquisition of AccessOne expands its healthcare payment and financing capabilities, while it highlights its integrated software and patient engagement platform's role in supporting 180 million patient visits in fiscal 2026. Phreesia also reported a net income of $2.3 million for fiscal year 2026, a significant improvement from a net loss in the previous fiscal year, and has refinanced a bridge loan with a new $275 million revolving credit facility.
KeyBanc reiterates Overweight on Phreesia stock, keeps $28 target
KeyBanc has reiterated its Overweight rating and $28 price target on Phreesia Inc. despite the company reporting a fourth-quarter beat but lowering its fiscal 2027 revenue guidance by 7%, primarily due to reduced advertising spend commitments from pharmaceutical clients. This guidance cut has led several other analyst firms to reduce their price targets for Phreesia, reflecting concerns about its financial outlook. Despite these challenges, InvestingPro analysis suggests Phreesia is undervalued and has a "GREAT" financial health score.
Phreesia, Inc. (NYSE:PHR) Q4 2026 Earnings Call Transcript
Phreesia, Inc. reported its Q4 and full fiscal year 2026 earnings, surpassing expectations with an EPS of $0.12 against an anticipated $0.06571. The company achieved significant financial milestones, including positive GAAP net income and over $100 million in Adjusted EBITDA for the fiscal year, driven by strategic acquisitions like AccessOne and the launch of ProviderConnect. Despite these successes, Phreesia faces reduced visibility in its Network Solutions business due to external pharmaceutical spending dynamics, leading to a lowered revenue outlook for fiscal year 2027 while maintaining its Adjusted EBITDA guidance through efficiency gains and AI adoption.
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Several prominent stocks, including Phreesia, Service Properties Trust, and Inventiva, are experiencing downturns in Tuesday's pre-market session. Phreesia's shares tumbled after reporting mixed quarterly financial results and cutting its FY27 sales guidance. Service Properties Trust declined following an announcement of a $500 million public offering, while Inventiva ADR fell after posting a FY loss.
Phreesia Inc reports results for the quarter ended January 31 - Earnings Summary
Phreesia Inc announced its earnings summary for the quarter that ended on January 31. This brief report, sourced from Refinitiv, provides key financial information for the company, Phreesia Inc (PHR).
Phreesia Announces Fourth Quarter Fiscal 2026 Results
Phreesia (NYSE: PHR) announced its financial results for the fourth quarter and fiscal year ended January 31, 2026, reporting positive GAAP net income and exceeding $100 million in Adjusted EBITDA and $50 million in free cash flow for the fiscal year. The company confirmed the AccessOne acquisition and a subsequent refinancing of its Bridge Loan with a new $275 million revolving credit facility. Phreesia also provided its fiscal 2027 outlook, lowering revenue expectations due to decreased visibility into pharmaceutical manufacturer spending but maintaining its Adjusted EBITDA outlook, citing efficiencies from AI adoption.
Phreesia: Fiscal Q4 Earnings Snapshot
Phreesia Inc. (PHR) reported stronger-than-expected fiscal fourth-quarter earnings and revenue, with net income of $1.3 million and adjusted earnings of 12 cents per share, surpassing analyst estimates. The healthcare software developer posted $127.1 million in revenue for the quarter and projects full-year revenue between $510 million and $520 million.
Phreesia: Fiscal Q4 Earnings Snapshot
Phreesia Inc. (PHR) reported fiscal fourth-quarter earnings of $1.3 million, or 2 cents per share, which exceeded Wall Street expectations. Adjusted earnings were 12 cents per share, beating the average analyst estimate of 9 cents. The healthcare software developer also reported revenue of $127.1 million, surpassing forecasts, and anticipates full-year revenue between $510 million and $520 million.
Phreesia (NYSE:PHR) CFO Sells $43,114.54 in Stock
Phreesia (NYSE:PHR) CFO Balaji Gandhi sold 3,829 shares of the company's stock for $43,114.54 on March 25th, reducing his stake by 2.54%. This sale follows earlier transactions in January totaling approximately $229,000. Phreesia currently has a market capitalization of $660.5 million, a "Moderate Buy" consensus rating from analysts, and a target price of $28.65.
Phreesia (PHR) CFO tax-related sale of 3,829 shares disclosed
Phreesia's CFO, Balaji Gandhi, reported a routine, non-discretionary sale of 3,829 shares of common stock at a weighted average price of $11.2635 per share. This transaction was executed to cover tax withholding obligations related to the settlement of restricted stock units. After the sale, Gandhi directly retains 146,740 shares, indicating this was a compensation-related event with limited implications for investors rather than an active portfolio decision.
Mizuho lowers its price target on Phreesia (PHR) to $19
Mizuho has adjusted its price target for Phreesia (PHR) downwards to $19.
Mizuho lowers its price target on Phreesia (PHR) to $19
Mizuho has lowered its price target for Phreesia (PHR) to $19.
Mizuho Lowers its Price Target on Phreesia (PHR) to $19
Mizuho analyst Steven Valiquette lowered the price target for Phreesia, Inc. (NYSE:PHR) to $19 from $22, while maintaining an Outperform rating. The adjustment comes ahead of the company's fiscal Q4 report, reflecting a more conservative outlook on estimates. Phreesia also recently refinanced its bridge loan with a new $275 million credit agreement.
Mizuho Lowers its Price Target on Phreesia (PHR) to $19
Mizuho analyst Steven Valiquette revised Phreesia's (NYSE:PHR) price target down to $19 from $22, while maintaining an Outperform rating, due to a more conservative outlook ahead of the company's Q4 report. This follows Phreesia's refinancing of its bridge loan into a new $275M credit agreement. JPMorgan had also previously lowered its price target for the SaaS-based healthcare platform provider.
Tudor Investment Corp ET AL Makes New $4.17 Million Investment in Phreesia, Inc. $PHR
Tudor Investment Corp ET AL has made a new $4.17 million investment in Phreesia, Inc. (NYSE:PHR), acquiring 177,409 shares during the third quarter. This new stake represents 0.30% of Phreesia, while other hedge funds also modified their positions. Despite recent insider selling and price target cuts by some analysts, the company maintains a "Moderate Buy" consensus rating with an average target price of $28.94.
10 Small–Cap Stocks Insiders Are Buying Recently
This article highlights Phreesia, Inc. (NYSE:PHR) as one of the small-cap stocks insiders are buying. It notes that analysts have recently adjusted price targets for PHR, and the company refinanced its bridge loan with a new credit facility. Phreesia provides a SaaS-based software and payment platform for healthcare providers.
10 Small–Cap Stocks Insiders Are Buying Recently
This article focuses on small-cap stocks that have recently seen insider buying activity. It highlights Phreesia, Inc. (NYSE:PHR), detailing recent analyst price target adjustments, refinancing activities, and its business as a SaaS-based software and payment platform for healthcare providers. The piece is part of a larger list of small-cap stocks.
Vanguard disaggregates holdings; reports 0 shares in Phreesia (PHR)
The Vanguard Group has filed an Amendment No. 4 to Schedule 13G/A, reporting that it beneficially owns 0 shares of Phreesia Inc common stock, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. This disaggregation of holdings means Vanguard itself no longer has beneficial ownership over securities held by these subsidiaries.
EBIT per share of Phreesia, Inc. – SWB:19P
This article focuses on the EBIT per share for Phreesia, Inc. (SWB:19P) listed on the Stuttgart Stock Exchange. It appears to be a financial data page from TradingView, displaying "Period Value Change Change %" for the EBIT per share, indicating a financial overview rather than an in-depth analysis. The content primarily lists general market and company information provisions and copyright details.
Pale Fire Capital SE Increases Stake in Phreesia Inc by 37.25%
Pale Fire Capital SE significantly increased its stake in Phreesia Inc by 37.25% on March 17, 2026, acquiring an additional 2,076,005 shares at $11.19 per share. This transaction reflects Pale Fire Capital's confidence in Phreesia's future growth, despite the latter's year-to-date price decline. Phreesia, a healthcare software solutions provider, is considered significantly undervalued by GuruFocus metrics.
Phreesia (NYSE:PHR) General Counsel Allison Hoffman Sells 6,176 Shares of Stock
Phreesia's General Counsel, Allison Hoffman, sold 6,176 shares of company stock on March 23rd at an average price of $11.97, totaling approximately $73,927. This sale reduced her holdings by 3.64%, leaving her with 163,485 shares. The stock is currently trading near its 52-week low, significantly below its high, and analysts maintain a "Moderate Buy" rating with an average price target of $28.94 despite recent target trims.
Phreesia’s Hoffman sells $73,926 in stock
Allison C. Hoffman, General Counsel & Secretary at Phreesia, Inc. (NASDAQ:PHR), sold 6,176 shares of common stock for $73,926. This transaction was part of a Rule 10b5-1 trading plan. The article also touches on Phreesia's recent refinancing, the launch of a new digital tool, and updated analyst ratings.
Phreesia’s Hoffman sells $73,926 in stock
Allison C. Hoffman, General Counsel & Secretary at Phreesia, Inc. (NASDAQ:PHR), sold 6,176 shares of common stock for $73,926, as part of a Rule 10b5-1 trading plan. This transaction occurred amidst various company developments, including a refinancing of its bridge loan and the launch of a new digital tool, ProviderConnect. Analyst firms Mizuho, DA Davidson, and Wells Fargo have also updated their ratings and price targets for Phreesia, reflecting diverse perspectives on the company's valuation and growth prospects.
Phreesia (PHR) counsel sells 6,176 shares under 10b5-1 plan
Phreesia's General Counsel & Secretary, Allison C. Hoffman, sold 6,176 shares of company common stock at $11.97 per share on March 23, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on December 19, 2025. Following the sale, Hoffman directly holds 163,485 shares of Phreesia common stock.
3,829-share sale tied to restricted vesting reported by PHR (PHR)
Phreesia (PHR) has filed a Form 144, indicating a proposed sale of 3,829 common shares originating from restricted stock vesting on March 24, 2026. Fidelity Brokerage Services LLC is listed as the broker for transactions on March 25, 2026. The filing also discloses prior sales by Balaji Gandhi in January 2026, totaling 8,009, 975, and 4,687 shares.
Earnings Preview: Phreesia to Report Financial Results Post-market on March 30
Phreesia (NYSE: PHR) is scheduled to announce its financial results after the market closes on March 30. Analysts expect the company to report a year-over-year decrease in earnings per share, paired with a significant increase in revenue. These figures will be crucial in assessing Phreesia's recent financial performance and future outlook.
Phreesia Named One of Becker’s Top Places to Work in Healthcare
Phreesia, a leader in patient intake, outreach, and activation, has been recognized for the second time as one of Becker’s Healthcare’s Top Places to Work in Healthcare for 2026. This acknowledgment highlights Phreesia’s commitment to its employees through strong benefits, professional development, and workplace practices that support engagement and retention, particularly as a fully remote company. The award reflects Phreesia's focus on connection, growth, and support for its teams to further its mission of making healthcare easier.
Phreesia Price Target Cut to $19.00/Share From $22.00 by Mizuho
Mizuho has reduced its price target for Phreesia (PHR) shares from $22.00 to $19.00. This adjustment maintains a "Neutral" rating on the stock.
Mizuho Lowers Price Target for Phreesia (PHR) to $19, Maintains Outperform Rating | PHR Stock News
Mizuho analyst Steven Valiquette has lowered the price target for Phreesia (PHR) from $22.00 to $19.00 but maintained an "Outperform" rating. This adjustment was announced on March 24, 2026, following several other firms that also revised their price targets for PHR in recent months. Despite the target reduction, the average analyst target price of $28.28 still implies a significant upside of 152.93% from the current price.
Phreesia (NYSE:PHR) Given New $19.00 Price Target at Mizuho
Mizuho has lowered its price target for Phreesia (NYSE:PHR) from $22.00 to $19.00, while maintaining an "outperform" rating, indicating a potential upside of 69.87% from its previous close. Despite this reduction, analyst consensus remains a "Moderate Buy" with an average price target of $28.94. The company's stock traded down 5.2% to $11.19, and recent insider transactions show sales totaling over $1 million.
Mizuho Securities Maintains Phreesia(PHR.US) With Buy Rating, Cuts Target Price to $19
Mizuho Securities has reiterated its Buy rating on Phreesia (PHR.US) but has lowered its target price for the stock to $19. This adjustment reflects an updated valuation while still expressing confidence in the company's prospects.
Mizuho cuts Phreesia stock price target on pharma spend concerns
Mizuho has lowered its price target for Phreesia Inc. (NYSE:PHR) to $19 from $22, while maintaining an Outperform rating, due to concerns over pharmaceutical marketing spend. The firm also reduced its fiscal 2027 revenue and EBITDA estimates for the company. Despite the downward revision, other recent developments include a refinancing of Phreesia's bridge loan and the launch of a new digital tool, ProviderConnect, alongside varying analyst price targets from DA Davidson and Wells Fargo.
Mizuho cuts Phreesia stock price target on pharma spend concerns
Mizuho reduced its price target for Phreesia Inc. (NYSE:PHR) from $22 to $19, maintaining an Outperform rating, due to concerns over pharmaceutical marketing spend and a more conservative outlook for its Network Solutions business. The firm also lowered its fiscal 2027 revenue and EBITDA estimates. Despite these adjustments, InvestingPro analysis indicates the stock is undervalued, while other analysts like DA Davidson and Wells Fargo have offered higher price targets with Buy or Overweight ratings, citing different long-term growth drivers and market positions.
Allison Hoffman reports share sales at PHR (NYSE: PHR) on three January dates
Allison C. Hoffman, an insider at Phreesia, Inc. (NYSE: PHR), filed a Form 144 reporting proposed sales of Common Stock on three separate dates in January 2026, totaling over 11,000 shares for gross proceeds exceeding $195,000. The filing also detailed the acquisition of these securities through restricted stock vesting and an ESPP purchase. This Form 144 serves as a notice of proposed sales and does not confirm their completion.
Phreesia (PHR) Projected to Post Earnings on Monday
Phreesia (PHR) is expected to announce its Q4 2026 earnings on Monday, March 30th, with analysts forecasting EPS of $0.0657 and revenues of $126.75 million. The stock currently trades near its 52-week low with a negative P/E ratio, indicating ongoing unprofitability. Despite significant institutional investment, insiders have recently sold shares, while analysts maintain a "Moderate Buy" consensus with a target price of $29.12.
Phreesia (PHR) stock jumps 5.1%: Will it continue to soar?
This article discusses the 5.1% jump in Phreesia (PHR) stock and questions whether this upward trend will continue. The content provided is minimal, offering only a headline and an inquiry into the stock's future performance.
Pale fire capital group buys Phreesia (PHR) shares worth $18.3 million
A group including Pale Fire Capital SE and other entities purchased 1,602,505 shares of Phreesia, Inc. (NASDAQ:PHR) worth $18.3 million between March 17 and March 19, 2026. This acquisition increased their stake to 7,648,829 shares, occurring while PHR's stock has declined significantly and is trading near its 52-week low. Analyst ratings suggest the stock is undervalued, with price targets between $22 and $35.
